Professor Yosef Karako, the lead researcher of the Israeli vaccine against COVID-19, was interviewed on Reshet Bet radio on Monday evening.
"We are nearing the end of the second phase of research into the drug of the 'NSD' company given to COVID-19 patients in mild condition. The Israeli vaccine is also at the highest dose at the end of the second phase, and within a month or two we will be able to publish results and move to the third stage," he said.